A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

Trial Profile

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs Sorafenib (Primary) ; Doxorubicin
  • Indications Liver cancer
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms SPACE
  • Sponsors Bayer
  • Most Recent Events

    • 22 Jan 2016 Results published in the Journal of Hepatology
    • 21 Sep 2012 Planned end date changed from 1 Jul 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS0000366).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top